Compare Atmos Energy Corporation (ATO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Novo Nordisk A/S — how do they compare? Atmos Energy Corporation trades at $169.09 (market cap $28.59B), while Novo Nordisk A/S trades at $46.47 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 7.3× Atmos Energy Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ATO | NVO | |
|---|---|---|
Market Cap | $28.59B | $207.85B |
Sector | Utilities | Health |
52-Week High | $192.25 | $63.98 |
52-Week Low | $162.44 | $35.29 |
Enterprise Value | $38.40B | $222.55B |
Dividend Yield | 2.36% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $169.68, up 1.05% today, with a bearish technical signal but strong fundamentals including a 28.5% net income margin and consistent dividend payments. Recent Q3 2026 earnings beat estimates with EPS of $1.43 versus $1.35 expected, and the company reaffirmed fiscal 2026 guidance. The stock shows neutral oscillators but bearish moving averages, with key support at $168.
The outlook is mixed: analyst consensus is a Buy with a $190.57 price target, but technical indicators suggest near-term caution. Risks include high capital expenditures impacting cash flow and interest rate sensitivity. Upside potential hinges on execution of rate hikes and infrastructure investments, while downside risks involve regulatory changes and economic slowdowns.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
